Abstract
To the Editor: In the DEDICATE trial (Randomized, Multicenter, Event-Driven Trial of TAVI versus SAVR in Patients with Symptomatic Severe Aortic-Valve Stenosis), Blankenberg et al. (May 2 issue)1 attempt to address the most effective treatment of isolated severe aortic stenosis in low- or intermediate-risk groups and conclude that transcatheter aortic-valve implantation (TAVI) is noninferior to surgical aortic-valve replacement (SAVR) at 1 year. However, the results reported for the SAVR group in this trial differ widely from real-world outcomes. Other studies, including those that had a composite of high, intermediate, and low surgical risk groups, have shown lower mortality than that .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
